Shareholders

We introduce ADBIOTECH’s technology intended to replace vaccines and antibiotics.

ShareholdersAs of Mar. 31, 2021

Dividend

Classification FY2018 FY2019 FY2020
Face value (KRW) 500 500 500
(Consolidated) Net profit (KRW in millions) 350,241 350,241 350,241
Total cash dividends (KRW in millions) 350,241 350,241 350,241
Dividend propensity (%) 74.2 74.2 74.2
Cash dividend per share (KRW) 3,600 3,600 3,600
Cash dividend propensity (%) 4.6 4.6 4.6